The Patent Finder

Qaam Pharmaceuticals, LLC

9 patents currently held · Updated Nov 15, 2026
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
7
Ending by 2030
Nov 2027
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Nov 19, 2026
    The maintenance fee for Combined acetylcholinesterase inhibitor and quaternary ammonium antimuscarinic therapy to alter progression of cognitive diseases (US 9,034,890) comes due Nov 19, 2026. Unpaid by May 19, 2027, it lapses early.
  • 1 fee due Jan 21, 2027
    The maintenance fee for Uses for quaternary ammonium anticholinergic muscarinic receptor antagonists in patients being treated for cognitive impairment or acute delirium (US 9,084,753) comes due Jan 21, 2027. Unpaid by Jul 21, 2027, it lapses early.
  • 1 fee due Feb 13, 2027
    The maintenance fee for Combined acetylcholinesterase inhibitor and quaternary ammonium antimuscarinic therapy to alter progression of cognitive diseases (US 10,376,493) comes due Feb 13, 2027. Unpaid by Aug 13, 2027, it lapses early.
  • 1 fee due Jun 30, 2027
    The maintenance fee for Glycopyrronium Fatty Acid Salts and Methods of Making Same (US 10,519,109) comes due Jun 30, 2027. Unpaid by Jan 3, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Showing 1 to 9 of 9

PatentTitleStatus Expires Confidence
US 8,969,402Combined Acetylcholinesterase Inhibitor and Quaternary Ammonium Antimuscarinic Therapy to Alter Progression of Cognitive Diseases
In force
 · Medium confidence
In forceMedium confidence
US 9,034,890Combined acetylcholinesterase inhibitor and quaternary ammonium antimuscarinic therapy to alter progression of cognitive diseases
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,980,941Quaternary ammonium anti-cholinergic muscarinic receptor antagonists
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,376,493Combined acetylcholinesterase inhibitor and quaternary ammonium antimuscarinic therapy to alter progression of cognitive diseases
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,419,850Combined acetylcholinesterase inhibitor and quaternary ammonium antimuscarinic therapy to alter progression of cognitive diseases
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,084,753Uses for quaternary ammonium anticholinergic muscarinic receptor antagonists in patients being treated for cognitive impairment or acute delirium
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,097,633Uses for quaternary ammonium anticholinergic muscarinic receptor antagonists in patients being treated for cognitive impairment or acute delirium
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,519,109Glycopyrronium Fatty Acid Salts and Methods of Making Same
In force
 · High confidence
In forceHigh confidence
US 12,109,202Fixed Dose Combination of Cholinesterase Inhibitor and a Quaternary Ammonium Antimuscarinic Agent to Treat Neurodegenerative Cognitive Disorders
In force
 · High confidence
In forceHigh confidence

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

1 pending

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited